Namperumalsamy, Aravind Eye Hospital chairman, passes away in Madurai
Born in July 9, 1940, in a small hamlet with an agricultural background in Theni district, he did his MBBS from Madurai Medical College and moved to Boston, USA, to pursue higher education. He was the first retina specialist in the country. He practised in the Erskine Hospital Madurai, (now known as Government Rajaji Hospital) before starting his own venture, his elder son N. Venkatesh Prajna, said.
Dr. Namperumalsamy received the Padma Shri in 2007 for his immense contributions in the field of Ophthalmology. He received several awards through the course of an illustrious, and long career.
The cremation is expected to be performed at Ambasamudram in Theni district on Friday (July 25). He leaves behind his wife Nachiar and two sons - Venkatesh Prajna and Vishnu Prasad.
Condolences
Amar Agarwal, chairman, Dr. Agarwals Group of Eye Hospitals said Dr. Namperumalsamy was a doyen in Ophthalmology. 'What the Aravind eye care group has created under his leadership is just phenomenal. His contribution is not only in the number of patients he treated, which was huge, but also the number of doctors he trained. All these doctors are treating patients all over the world and helping eradicate blindness. The legacy he has left being will remain forever.'
Mohan Rajan, chairman and medical director, Rajan Eye Care Hospital, said, 'Dr NAM is no more, but his legacy lives on. Very rarely do we see a combination of a great teacher, great clinician, fantastic surgeon, great researcher, good speaker and an able administrator in one person, he was all of this,' he said.
Dr NAM, along with Dr Badrinath, was one of the earliest movers as far as the vitreoretinal surgery was concerned in this part of the world. 'He is a great inspiration, a role model and a motivation for all the ophthalmologists in the country and across the world. He has literally put India in a prominent position in the world map of Ophthalmology,' he added.
C. Ramasubramanian, psychiatrist and founder M.S. Chellamuthu Trust & Research Foundation said Dr NAM was concerned for the differently-abled population. He was instrumental in popularising the 'Arvind model' which tried to take ophthalmological care to all people irrespective of passing capacity. Dr. NAM had also advocated for community psychiatry, in order to make it more accessible, Dr CRS said and recalled an event where the late President APJ Abdul Kalam was amazed during his visit to Aravind Eye Hospital over the seamless doctor-patient care rendered on a mass scale.
Hari Thiagarajan, managing director, Thiagarajar Mills said Dr NAM was Madurai's pride. 'He was an alumni of Thiagarajar College and a well wisher of the institution. He continued the visionary path set by the founder of Aravind Eye Care and provided the group with moral and outstanding leadership. Under his tutelage, Aravind expanded and grew in great measure. 'He was a gentle person and care for the betterment of society especially, the rural India,' Mr. Thiagarajan added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
First Post
2 hours ago
- First Post
‘1 in 5 children in Gaza City is malnourished': Where's the food aid?
After 21 months of the Israel war, the people in Gaza are facing acute shortages of food, resulting in 'mass starvation' and causing unprecedented levels of malnourishment. What's behind this humanitarian crisis in the Palestinian area? read more A little infant's body rests on the table at Gaza City's Al Shifa hospital. As hospital staff remove the clothing off the infant's body what they see is appalling — protruding ribs and hollow stomach. But the tiny toddler isn't a one-off case. Extreme hunger is resulting in malnutrition and deaths in the besieged enclave with the UN's Palestinian refugee agency (UNRWA) saying that one in five children in Gaza City is malnourished and cases are increasing every day. STORY CONTINUES BELOW THIS AD In a statement issued on Thursday, Unrwa Commissioner-General Philippe Lazzarini cited a colleague telling him: 'People in Gaza are neither dead nor alive, they are walking corpses.' But why is this happening? Why are all 2.1 million people in Gaza are now food insecure? GHF: Few sites and deadly violence Israel's chosen aid distributor, the Gaza Humanitarian Foundation (GHF), began operations on May 26 after a more than two-month total aid blockade. Now the main channel for distributing food to Gaza, GHF has faced chaos and deadly violence at its few distribution points. The United Nations and aid groups have refused to work with GHF, saying it was created to serve Israeli military interests. 'They are not a humanitarian organisation… You don't deliver humanitarian aid in areas that have been completely flattened and militarised,' said Arwa Damon, founder of INARA, a US-based NGO offering medical and mental health support to children. She noted the GHF's site locations — along two military corridors in southern and central Gaza — rather than being spread out across the territory. Displaced Palestinians receive donated food at a community kitchen in Gaza City, northern Gaza Strip. AP Today, there are only four GHF sites in Gaza — Tal al-Sultan, Saudi neighbourhood, Khan Younis and Wadi Gaza. These are open only for eight minutes at a time and in June, the average for the Saudi site was 11 minutes. This has led to many to allege that system is dangerous by design. The Unrwa chief, Philippe Lazzarini, even said 'the so-called mechanism … is a death trap costing more lives than it saves.' In fact, according to UN figures, Israeli forces have killed nearly 900 desperate and hungry Gazans near GHF sites until July 13. Israel has rejected calls to restore the UN-led system, citing concerns that Hamas looted trucks and resold aid meant to be distributed free of charge. Aid organisations sidelined Another reason for the dire conditions in Gaza according to international aid groups is Israel itself. They note that vast quantities of food are stockpiled outside Gaza but await clearance from the Israeli military. Furthermore, inside Gaza, coordination with the military is also essential, as fighting and air strikes rage on. Damon accuses Israel of preventing aid delivery by refusing to coordinate with NGOs to grant safe passage through combat zones. STORY CONTINUES BELOW THIS AD 'Getting that coordination approved is incredibly challenging,' she told AFP. 'Not to mention Israel's lack of willingness to provide humanitarian organisations with a safe route to be able to ensure a secure pickup.' The UN agency for Palestinian refugees, UNRWA, said on Wednesday it had 'thousands of trucks in neighbouring countries waiting to enter Gaza — banned by Israeli authorities from entering since March'. Displaced Palestinian mother Samah Matar holds her malnourished son Youssef, who suffers from cerebral palsy, at a school where they shelter amid a hunger crisis, in Gaza City. Reuters Israel blames UN However, the Jewish nation denies limiting the number of humanitarian trucks into Gaza. On Thursday, it even posted footage online of hundreds of trucks with aid 'sitting idle inside Gaza'. Moreover, Israel's Foreign Minister Gideon Sa'ar told Politico that Israel had opened up more crossing points and was allowing more aid to enter Gaza under a deal struck with the European Union. He added that the problem was that the UN was failing to distribute more than 900 truckloads of aid parked in a fenced-off area near the Kerem Shalom crossing point in the Gaza Strip. 'The problem is the UN is not distributing [aid],' said Sa'ar. 'There are more than 900 trucks waiting … inside Gaza Strip, and they are just not distributing them to the people in Gaza.' STORY CONTINUES BELOW THIS AD UN agencies and international NGOs reject Israeli claims that they lack the capacity to distribute food. They note that aid was distributed effectively in the past, including during the last ceasefire in the Israel-Hamas war that ended in March. A father clings to the body of his infant who died of starvation according to health officials, in Gaza City. Reuters 'There's just no food' For people in Gaza, this has resulted in a nightmare. The few doctors inside Gaza say the mounting hunger crisis is horrific is hitting women and children the hardest. As American surgeon Ambereen Sleemi told NBC News that the neonatal intensive care unit was 'full of babies that are malnourished that have struggled to get formula or get feeding.' She added that in many cases the lack of nutrition had led to other health complications, including a surge in infection rates. Elidalis Burgos, an American critical care nurse volunteering in Gaza, further told NBC News that she had witnessed 'an entire population' suffering from starvation because of the Israeli blockade. 'There's just no food,' said Burgos, who is working at Nasser Hospital in Khan Younis. 'There is just nothing getting in, hasn't been getting in for months.' Walaa Fathi, a resident of Gaza who is eight months pregnant, wailed about the situation, saying that Gazans were 'experiencing a catastrophe and a famine that no one could have imagined'. 'I hope that my baby stays in my womb and I don't have to give birth in these difficult circumstances,' she was quoted as telling the BBC from Deir al-Balah. STORY CONTINUES BELOW THIS AD With inputs from AFP and agencies
Time of India
5 hours ago
- Time of India
Trump administration asks US Supreme Court to allow NIH diversity-related cuts
New York: Donald Trump's administration asked the U.S. Supreme Court on Thursday to allow the government to proceed with sweeping cuts to National Institutes of Health grants as part of the Republican president's crackdown on diversity initiatives. The Justice Department asked the justices to lift Boston-based U.S. District Judge William Young's June ruling that halted the plan as a violation of federal law and required the government to reinstate access to the grant funds. The judge acted in a legal challenge by researchers and 16 U.S. states, led by Democratic-governed Massachusetts. The NIH is the world's largest funder of biomedical research. The cuts are part of Trump's wide-ranging actions to reshape the U.S. government, slash federal spending and end government support for diversity, equity and inclusion programs and transgender healthcare. The administration repeatedly has sought the Supreme Court's intervention to allow implementation of Trump policies impeded by lower courts. The Supreme Court, which has a 6-3 conservative majority, has sided with the administration in almost every case that it has been called upon to review since Trump returned to the presidency in January. In June, dozens of scientists, researchers and other NIH employees signed an open letter criticizing the agency's actions and spending cuts under Trump that they said politicize research and "harm the health of Americans and people across the globe." Young's ruling came in two lawsuits challenging the cuts. One was filed by the American Public Health Association, individual researchers and other plaintiffs who called the cuts an "ongoing ideological purge" of projects with a purported connection to gender identity, DEI "or other vague, now-forbidden language." The other was filed by the states, most of them Democratic-led. Young, an appointee of Republican former President Ronald Reagan, invalidated the grant terminations in June. The judge wrote that every new administration is entitled to make policy changes but that these must be reasonable and reasonably explained. Instead, according to the judge, the steps taken by Trump administration officials were "breathtakingly arbitrary and capricious," violating a federal law governing the actions of agencies. Young criticized administration officials for not offering any definition of DEI while disparaging studies they deemed low-value and unscientific that the officials claimed were used to unlawfully discriminate on the basis of race and other protected characteristics. "There is not a shred of evidence supporting any of these statements in the record," Young wrote. Many U.S. conservatives contend that DEI policies discriminate against white people. The Boston-based 1st U.S. Circuit Court of Appeals on July 18 denied the administration's request to put Young's decision on hold. The administration has argued that the litigation should have been brought in a different judicial body, the Washington-based Court of Federal Claims, which specializes in money damages claims against the U.S. government. That reasoning was also the basis for the Supreme Court's decision in April that let Trump's administration proceed with millions of dollars of cuts to teacher training grants also targeted under the DEI crackdown.
Mint
6 hours ago
- Mint
India has the potential to be a global lab for scalable longevity solutions: Accel's Prashanth Prakash
Bengaluru-based wellness startup Biopeak had raised $3.5 million recently in a funding round led by Prashanth Prakash, founding partner of Accel Partners, that also saw participation from Manipal Group's Ranjan Pai through his investment vehicle Claypond Capital and Zerodha's Nikhil Kamath and Nithin Kamath. In this exclusive interview, Prakash talks about longevity as a concept and its importance in future. Excerpts: Hello Prashanth, what was the thought process behind this investment decision? The timing of this investment is deeply intentional. We are at a unique intersection in human health where diagnostics, artificial intelligence, and longevity science are converging with extraordinary speed. Biopeak is building an integrated, precision health system grounded in global science but tailored to the unique biological, environmental, and lifestyle factors of the Indian population. This is not just a business bet—it's a belief that India will lead the world in next-generation healthcare. The thought process was simple: medicine is shifting from reactive to predictive and preventive, and Biopeak is among the few platforms architecting that future in a scalable, scientifically grounded way. It will enable us to plot with unprecedented detail personalised health trajectories for a specific individual using multi-dimensional data collection, integration, and prediction. The focus on deeply personalised healthcare is going to be huge in the future. Right? The transition from universal averages to personalised insights will represent a revolution in how we detect, predict, prevent adverse events and build resilience reserves. This new model of Biology and AI-led medicine is an exciting paradigm for the future of healthcare in our country that investors are excited to back. What's your definition of longevity? Longevity, for us, is not merely about extending the lifespan but expanding the healthspan. Ensuring more years that are healthy, vital, and productive is more crucial. In the Indian context, this requires a unique balance: respect for traditional knowledge systems, alignment with evolving regulatory frameworks, and deep reliance on evidence-based science. We're combining cutting-edge diagnostics—from microbiome and metabolomics to imaging and functional genomics—with culturally compatible interventions and a powerful AI layer. Longevity for us in India means democratising access to health optimisation—life partnerships between human intelligence and machine precision, rooted in science, ethics, and scale. In ancient civilizations including India, people were said to have lived for a much longer span of time. How do you relate that to the work Biopeak is doing and the results it is hoping to achieve? While environmental and societal contexts have changed drastically, ancient systems often emphasised internal balance, rhythm with nature, and preventative health —all are core principles in today's longevity science. At Biopeak, we're not romanticising the past—we're modelling it. Using symbolic and generative AI frameworks, we're integrating timeless health principles with modern biological data to predict individual responses to pharmaceuticals, nutraceuticals, and lifestyle interventions. It's not about replicating ancient lifespans—it's about reclaiming biological potential by harmonising past wisdom with today's precision tools. Do you think longevity as a concept can be realistically spread to all sections of society? Or will it remain only an aspiration of the well-heeled? Longevity must not become a luxury. With AI at the core of Biopeak's platform, we can rapidly model and scale health solutions based on outcomes from higher-touch cases to broader population needs. What starts with the few can be democratised for the many through intelligent design, efficient diagnostics, and continuous learning from diverse cohorts. India has the potential to be a global lab for scalable longevity solutions—not by diluting science but by deploying it with cultural and economic sensitivity. Through our own longitudinal data leveraging interdisciplinary collaboration (Longevity India, an initiative of the Indian Institute of Science), we aim to identify markers of organ system malfunction before pathology sets in so that we can implement a health management program which will extend healthspan and improve the quality of life for the ageing population across all sections of society. At the core of Biopeak's offering, I believe, is a diagnostic system that includes tests like organic acid profiling, microbiome mapping, salivary cortisol rhythms, and whole-exome functional genomics. These are paired with imaging tools such as MRI, CT, and ECHO, as well as tissue-level screenings that examine markers like mineral levels, toxin load, and oxidative stress. Does this make Biopeak a unique company in the world? Yes, Biopeak is unique both in its scientific architecture and its population focus. It combines multiple high-resolution diagnostic modalities—molecular, functional, and structural—into a unified health intelligence platform. Each individual is paired with a biologist and clinician, and guided through a dynamic health roadmap. What further sets it apart is its South Asia-centric design, which considers the genetic, dietary, cultural, and environmental nuances of this region. Supported by research from institutions like IISc and informed by global best practices, Biopeak is not just another health company—it's a systems-level rethink of what human health can be in the 21st century. What's Medicine 4.0? What does it look to solve? What are its basic principles? Medicine 4.0 is the natural evolution of healthcare in the age of AI and high-resolution biology. It's defined by its longitudinal view of health, multisystem diagnostics, real-time feedback loops, and personalised intervention frameworks. It's not about treating symptoms—it's about continuously adapting to the evolving biology of the individual. This approach integrates international technologies, leverages big data with small, precise insights, and focuses on outcomes over time rather than episodic care. In short, it's predictive, participatory, personalised, and preventive. What do you think are the key pillars of the Medicine 4.0 framework as far as BioPeak is concerned? Biopeak leverages data from modern genomics, metabolomics, lipidomics, and metagenomics analytics to provide a molecular view of an individual's unique biology. This integration identifies systemic equilibrium for identifying subtle imbalances and hidden dysfunctions long before symptoms arise. From DXA scans for bone density to functional MRIs and real-time metabolic imaging, Biopeak employs cutting-edge tools that visualise internal systems and structural health markers. Using a hybrid AI approach, combining symbolic AI (for precise, rule-based interpretations) and generative AI (for pattern recognition and predictive modelling), Biopeak can detect complex biological interrelations and generate personalised health insights. What do you think are the limitations of the current health systems worldwide and in India? Globally and in India, health systems remain largely reactive, fragmented, and oriented around acute interventions rather than long-term prevention. There's a heavy focus on managing disease rather than predicting and reversing the conditions that lead to it. What's missing is a systems view—an integration of diagnostics, therapeutics, and lifestyle within a cohesive, continuously updating framework. People are treated as conditions, not as dynamic ecosystems. Long-term biological consequences of current choices are rarely factored into care. The foundation of Medicine 2.0 was built on population averages, with protocols and interventions developed based on data from extensive observational and interventional studies. While this approach helped standardise treatments, it does not account for individual variability. Each person's genetic framework, metabolism, lifestyle, and environment interactions are unique, making the n=1 (individual-first) model essential for true health optimisation. Biopeak is solving for precisely this: unifying the fragmented landscape into an intelligent, longitudinal system centred around the individual.
